Ignite Creation Date:
2025-12-24 @ 11:54 PM
Ignite Modification Date:
2025-12-25 @ 9:50 PM
Study NCT ID:
NCT03471351
Status:
TERMINATED
Last Update Posted:
2019-12-27
First Post:
2018-02-15
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL
Sponsor:
Rhizen Pharmaceuticals SA
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-07-18
Start Date Type:
ACTUAL
Primary Completion Date:
2019-02-13
Primary Completion Date Type:
ACTUAL
Completion Date:
2019-02-13
Completion Date Type:
ACTUAL
First Submit Date:
2018-02-15
First Submit QC Date:
None
Study First Post Date:
2018-03-20
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-12-24
Last Update Post Date:
2019-12-27
Last Update Post Date Type:
ACTUAL